----item----
version: 1
id: {923E465B-0B86-41E5-8B7A-915896C142A7}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/07/14/Valeant expands emerging market presence
parent: {CDA12E48-3499-4F0B-8DA5-8FF067DDAF1D}
name: Valeant expands emerging market presence
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 38e1a9f6-0c4c-4ac9-ad04-ec5ded01efff

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{78485A7A-B73F-43C5-A545-3DC6EC60C23B}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 40

Valeant expands emerging market presence
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 40

Valeant expands emerging market presence
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1537

<p><p>Always acquisitive Valeant Pharmaceuticals has made its first deal in the Middle East with a purchase of Egypt's Amoun Pharmaceuticals. </p><p>The Canadian company expects the deal to close in the third quarter and is paying $800m plus fees to buy the holding company owned by Concord International, Rohaytn Group and Capital International Group. </p><p>Amoun is the largest domestic pharmaceutical company in Egypt and expects to have sales of 1.75bn Egyptian pounds (US$223m) in 2015. The company currently has 30 products in its pipeline across varying stages of development and commercial in areas like anti-hypertensives antibiotics, analgesics and anti-diarrheals. </p><p>The deal gives Valeant its first presence in the Middle East and Africa and includes a manufacturing facility. </p><p>Valeant is on a tear to become one of the largest pharmaceutical companies in the world. Just five years ago, Valeant was a small Canadian company that specialized in topical dermatology products &ndash; revenues for the company have grown from $1.18bn in 2010 to $8.26bn in 2014. It is now a multinational company with assets in neurology, dermatology and infectious diseases. Valeant added eye care to its portfolio with the acquisition of Bausch + Lomb in 2013. Currently, emerging markets makes up less than a quarter of its total revenues. </p><p>Valeant is hosting its second quarter earnings call on 23 July; expect the company to talk about its strategy in emerging markets as it highlights the acquisition of Amoun. </p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 3

<p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 40

Valeant expands emerging market presence
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150714T220342
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150714T220342
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150714T220342
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029271
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 40

Valeant expands emerging market presence
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{2D771726-4AE8-4124-B380-232612225CB7}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359426
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042424Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

38e1a9f6-0c4c-4ac9-ad04-ec5ded01efff
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042424Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
